Neuronetics Stock

Neuronetics EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Neuronetics (STIM) as of Aug 4, 2026 is -3.44. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -2.89 — a change of 19.10% (lower).

EV/EBIT

-3.44

YoY

19.10%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Neuronetics is 2026 -3.44 . EV/EBIT (Enterprise Value to EBIT) of Neuronetics was 2025 -2.89 . It decreases by 19.10% lower compared to the previous year.

The Neuronetics EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2019
-0.45 base
Jan 1, 2020
-1.40 base
Jan 1, 2021
-1.11 base
Jan 1, 2022
-1.46 base
Jan 1, 2023
-0.72 base
Jan 1, 2024
-1.62 base
Jan 1, 2025
-3.10 base
Jan 1, 2026 (e)
-2.05 base
YEARPRICE-TO-EBIT
2026 est -2.05
2025 -3.10
2024 -1.62
2023 -0.72
2022 -1.46
2021 -1.11
2020 -1.40
2019 -0.45
2018 -1.55
2017 -
2016 -
Access this data via the Eulerpool API

Neuronetics Valuation

Details

Historical Valuation Multiples

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Neuronetics's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Neuronetics's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Neuronetics's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Neuronetics grows earnings faster than its peers.

Neuronetics Stock analysis

What does Neuronetics do? Neuronetics Inc is a globally leading company in the field of non-invasive neuromodulatory technology. It was founded in 2003 and is headquartered in Malvern, Pennsylvania. The company specializes in the development and production of transcranial magnetic stimulation devices that can be used in the treatment of psychiatric disorders, particularly severe depression. Neuronetics' business model is based on selling its patented technology, called NeuroStar Advanced Therapy, to medical facilities worldwide. The company works closely with leading psychiatrists and clinical neurophysiologists to ensure that their devices meet the highest quality standards and can provide the best possible help to patients. The company has achieved a number of significant milestones in recent years. For example, in 2008, it received the first FDA approval for its technology. Since then, Neuronetics has continuously developed and improved its technology and has also obtained approvals in Europe and other parts of the world. Neuronetics is divided into various divisions, including research and development, manufacturing, and sales. Each of these departments is focused on ensuring the highest quality standards and ensuring that the technology of NeuroStar Advanced Therapy meets the needs of patients and medical personnel. The technology of NeuroStar Advanced Therapy is based on transcranial magnetic stimulation (TMS), which uses gentle magnetic fields to stimulate the activity of certain brain regions. The stimulation can help restore the balance of neurotransmitters in the brain and thus alleviate depression. Treatment with NeuroStar Advanced Therapy has significant advantages over conventional antidepressant medications. In many cases, it leads to faster improvement of symptoms and does not cause any of the undesirable side effects that can occur with medication. Overall, Neuronetics has developed a revolutionary technology with NeuroStar Advanced Therapy that can help millions of people around the world overcome their depression. The company is proud to contribute to improving the quality of life for people and will continue to develop innovative solutions in the field of neuromodulatory technology in the future. Neuronetics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neuronetics stock

EV/EBIT (Enterprise Value to EBIT) of Neuronetics is -3.44 in 2026.

EV/EBIT (Enterprise Value to EBIT) of Neuronetics changed from -2.89 to -3.44, representing a 19.10% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) Neuronetics since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s Neuronetics with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Neuronetics

All Key Metrics — Neuronetics